Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
LYG
MCID: LYM051
MIFTS: 50

Lymphomatoid Granulomatosis (LYG)

Categories: Blood diseases, Immune diseases, Rare diseases, Respiratory diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Lymphomatoid Granulomatosis

About this section

MalaCards integrated aliases for Lymphomatoid Granulomatosis:

Name: Lymphomatoid Granulomatosis 38 76 53 59 55 73
Granulomatosis, Lymphomatoid 76
Lyg 59

Characteristics:

Orphanet epidemiological data:

59
lymphomatoid granulomatosis
Inheritance: Not applicable; Age of onset: Adult;

Classifications:

MalaCards categories:
Global: Rare diseases
Anatomical: Blood diseases Respiratory diseases Immune diseases
See all MalaCards categories (disease lists)
ICD10: 34
Orphanet: 59  
Rare haematological diseases


External Ids:

Orphanet 59 ORPHA86869
ICD10 via Orphanet 34 C83.8
MESH via Orphanet 45 D008230
UMLS via Orphanet 74 C0024307
UMLS 73 C0024307
Sources

Summaries for Lymphomatoid Granulomatosis

About this section
NIH Rare Diseases : 53 Lymphomatoid granulomatosis is a rare disorder characterized by an overproduction of white blood cells known as B lymphocytes. These B cells can build up in the tissues of the body, causing damage to the blood vessels. In many cases of lymphomatoid granulomatosis, the abnormal B cells contain the Epstein-Barr virus. The disease is more common in men, usually after the fifth decade of life. Lymphomatoid granulomatosis most commonly affects the lungs, though other areas of the body may also be affected. Signs and symptoms vary but can include cough, shortness of breath, tightness of the chest, fever, weight loss, and fatigue. Skin lesions and central nervous system changes such as headaches, seizures, and ataxia may also be seen. Rarely, the disorder can affect the kidneys or liver. The cause of the disorder is not well understood, though a combination of genetic and immune factors are thought to play a part. Treatment depends on the extent of the disease but may include interferon alfa-2b and combination chemotherapy with rituximab. Occasionally, the disorder resolves on its own without treatment. There has been some debate as to whether lymphomatoid granulomatosis should be viewed as a as a B-cell lymphoma or a lymphoproliferative disease or whether it should be viewed merely as a condition that can develop into a B-cell lymphoma. The prognosis is variable, though lymphomatoid granulomatosis can progress and become fatal in some cases. 

MalaCards based summary : Lymphomatoid Granulomatosis, also known as granulomatosis, lymphomatoid, is related to acquired immunodeficiency syndrome and viral infectious disease, and has symptoms including fever and malaise. An important gene associated with Lymphomatoid Granulomatosis is IFNA2 (Interferon Alpha 2), and among its related pathways/superpathways are Toll-like Receptor Signaling Pathway and Necroptosis. The drugs Ketamine and Ciprofloxacin have been mentioned in the context of this disorder. Affiliated tissues include lung, b cells and skin.

Wikipedia : 76 Lymphomatoid granulomatosis (LYG or LG) is a very rare lymphoproliferative disorder first characterized... more...

Sources

Related Diseases for Lymphomatoid Granulomatosis

About this section

Diseases related to Lymphomatoid Granulomatosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 116)
# Related Disease Score Top Affiliating Genes
1 acquired immunodeficiency syndrome 30.4 IFNA1 IFNA2
2 viral infectious disease 30.2 IFNA1 IFNA2
3 lymphomatoid papulosis 29.9 GZMB TIA1
4 myelofibrosis 29.4 IFNA1 IFNA2
5 lymphoproliferative syndrome 1 11.5
6 lymphoproliferative syndrome, x-linked, 1 11.3
7 lymphoma 10.6
8 arthritis 10.4
9 rheumatoid arthritis 10.4
10 leukemia 10.4
11 lymphosarcoma 10.3
12 b-cell lymphomas 10.2
13 lymphocytic leukemia 10.2
14 pneumonia 10.2
15 vasculitis 10.2
16 polymorphic reticulosis 10.2
17 leukemia, acute lymphoblastic 10.1
18 autoimmune lymphoproliferative syndrome, type v 10.1
19 hematopoietic stem cell transplantation 10.1
20 neuropathy 10.1
21 lethal midline granuloma 10.1
22 wiskott-aldrich syndrome 10.1
23 acute lymphoblastic leukemia, childhood 10.1
24 lung disease 10.1
25 large granular lymphocyte leukemia 10.1
26 orbit lymphoma 10.0 GZMB TIA1
27 lichen sclerosus et atrophicus 10.0 GZMB TIA1
28 viral esophagitis 10.0 GZMB TIA1
29 lymphocytic gastritis 10.0 GZMB TIA1
30 subcutaneous panniculitis-like t-cell lymphoma 10.0 GZMB TIA1
31 panniculitis 10.0 GZMB TIA1
32 primary cutaneous anaplastic large cell lymphoma 10.0 GZMB TIA1
33 composite lymphoma 10.0 GZMB TIA1
34 hepatosplenic t-cell lymphoma 10.0 GZMB TIA1
35 lichen planus 10.0 CXCL9 GZMB
36 natural killer cell leukemia 10.0 GZMB TIA1
37 choriocarcinoma of the testis 10.0 GZMB TIA1
38 giardiasis 10.0 GZMB TIA1
39 infiltrating lipoma 10.0 GZMB TIA1
40 alopecia areata 10.0 CXCL9 GZMB
41 necrotizing sialometaplasia 10.0 GZMB TIA1
42 ileum cancer 10.0 GZMB TIA1
43 angioimmunoblastic t-cell lymphoma 10.0 GZMB TIA1
44 reticulosarcoma 10.0 GZMB TIA1
45 b-cell expansion with nfkb and t-cell anergy 10.0 GZMB TIA1
46 peripheral t-cell lymphoma 10.0 GZMB TIA1
47 squamous papillomatosis 10.0 IFNA1 IFNA2
48 cryoglobulinemia, familial mixed 10.0 IFNA1 IFNA2
49 herpangina 9.9 IFNA1 IFNA2
50 hairy cell leukemia 9.9 IFNA1 IFNA2

Graphical network of the top 20 diseases related to Lymphomatoid Granulomatosis:



Diseases related to Lymphomatoid Granulomatosis
Sources

Symptoms & Phenotypes for Lymphomatoid Granulomatosis

About this section

UMLS symptoms related to Lymphomatoid Granulomatosis:


fever, malaise
Sources

Drugs & Therapeutics for Lymphomatoid Granulomatosis

About this section

Drugs for Lymphomatoid Granulomatosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 256)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
2
Ciprofloxacin Approved, Investigational Phase 3 85721-33-1 2764
3
Amoxicillin Approved, Vet_approved Phase 3 26787-78-0 33613
4 Orange Approved Phase 3
5
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
6
Vincristine Approved, Investigational Phase 3,Phase 2,Phase 1 57-22-7, 2068-78-2 5978
7
Iron Approved Phase 3,Phase 2,Phase 1,Not Applicable 7439-89-6 23925
8
Darbepoetin alfa Approved, Investigational Phase 3,Phase 2 11096-26-7, 209810-58-2
9
Ginseng Approved, Investigational, Nutraceutical Phase 3 50647-08-0
10
Glutamic Acid Approved, Nutraceutical Phase 3 56-86-0 33032
11 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
12 Central Nervous System Depressants Phase 3,Phase 1,Phase 2,Not Applicable
13 Peripheral Nervous System Agents Phase 3,Phase 2,Phase 1,Not Applicable
14 Excitatory Amino Acid Antagonists Phase 3
15 Neurotransmitter Agents Phase 3,Phase 2,Not Applicable
16 Anesthetics Phase 3
17 Anesthetics, Dissociative Phase 3
18 Anesthetics, Intravenous Phase 3
19 Analgesics Phase 3,Phase 1,Phase 2,Not Applicable
20 Anesthetics, General Phase 3
21 Excitatory Amino Acids Phase 3
22 Amoxicillin-Potassium Clavulanate Combination Phase 3
23 Antitubercular Agents Phase 3,Phase 2,Phase 1,Not Applicable
24 beta-Lactamase Inhibitors Phase 3
25 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
26 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1,Not Applicable
27 Clavulanic Acids Phase 3
28 Anti-Infective Agents Phase 3,Phase 2,Phase 1,Not Applicable
29 Cytochrome P-450 CYP1A2 Inhibitors Phase 3
30 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1,Not Applicable
31 Cytochrome P-450 Enzyme Inhibitors Phase 3,Phase 1,Phase 2
32 Narcotics Phase 3,Not Applicable
33 Analgesics, Opioid Phase 3,Not Applicable
34 Liver Extracts Phase 3,Phase 1,Phase 2
35 Adjuvants, Anesthesia Phase 3
36 Cola Phase 3,Phase 1,Phase 2
37 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
38 Antimitotic Agents Phase 3,Phase 2,Phase 1
39 ferric gluconate Phase 3
40 Hematinics Phase 3,Phase 2
41 Iron Supplement Phase 3
42 Ferric Compounds Phase 3
43
rituximab Approved Phase 1, Phase 2,Phase 2 174722-31-7 10201696
44
Busulfan Approved, Investigational Phase 2,Phase 1,Early Phase 1,Not Applicable 55-98-1 2478
45
Mycophenolic acid Approved Phase 2,Phase 1,Not Applicable 24280-93-1 446541
46
Fludarabine Approved Phase 2,Phase 1,Not Applicable 75607-67-9, 21679-14-1 30751
47
Miconazole Approved, Investigational, Vet_approved Phase 2,Phase 1,Not Applicable 22916-47-8 4189
48
Cyclophosphamide Approved, Investigational Phase 2,Phase 1,Early Phase 1,Not Applicable 6055-19-2, 50-18-0 2907
49
Gemcitabine Approved Phase 2,Phase 1 95058-81-4 60750
50
leucovorin Approved Phase 2,Phase 1,Not Applicable,Early Phase 1 58-05-9 6006 143

Interventional clinical trials:

(show top 50) (show all 179)
# Name Status NCT ID Phase Drugs
1 Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain Unknown status NCT01316744 Phase 3 ketamine hydrochloride
2 Early Hospital Discharge or Standard Inpatient Care in Cancer Patients Receiving Antibiotics for Febrile Neutropenia Unknown status NCT00445497 Phase 3 amoxicillin-clavulanate potassium;ciprofloxacin
3 Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial Completed NCT00750009 Phase 3
4 American Ginseng in Treating Patients With Fatigue Caused by Cancer Completed NCT00719563 Phase 3 American ginseng
5 Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain Completed NCT00666211 Phase 3
6 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
7 Glutamic Acid in Reducing Nerve Damage Caused by Vincristine in Young Patients With Cancer Completed NCT00369564 Phase 3 glutamic acid
8 Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With Cancer Completed NCT00661999 Phase 3 sodium ferric gluconate complex in sucrose
9 Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas Unknown status NCT01805037 Phase 1, Phase 2 brentuximab vedotin
10 Stem Cell Transplant in Treating Patients With Hematological Cancer or Other Disorders Unknown status NCT00740467 Phase 2 busulfan;cyclophosphamide;cyclosporine;fludarabine phosphate;mycophenolate mofetil
11 Gene Therapy for B-Cell Non-Hodgkin Lymphoma Using CD19 CAR Gene Transduced T Lymphocytes Unknown status NCT02134262 Phase 1, Phase 2 Cyclophosphamide or Bendamustine
12 Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies Completed NCT01789255 Phase 2 vorinostat;tacrolimus;cyclosporine;methotrexate
13 Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies Completed NCT01273766 Phase 2 deferasirox
14 Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies Completed NCT01427881 Phase 2 cyclophosphamide;cyclosporine;fludarabine phosphate;busulfan
15 Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies Completed NCT01093586 Phase 2 busulfan;cyclophosphamide;anti-thymocyte globulin;methylprednisolone;cyclosporine;mycophenolate mofetil
16 Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphoma Completed NCT00867529 Phase 2
17 Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer Completed NCT00118352 Phase 2 fludarabine phosphate;cyclosporine;mycophenolate mofetil
18 Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer Completed NCT00049504 Phase 2 cyclophosphamide;fludarabine phosphate;tacrolimus;mycophenolate mofetil
19 Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors Completed NCT01326702 Phase 1, Phase 2 Bendamustine Hydrochloride;Veliparib
20 Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma Completed NCT01258998 Phase 2 Akt inhibitor MK2206
21 High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin Lymphoma Completed NCT01177371 Phase 2 busulfan;cyclophosphamide;methylprednisolone;methotrexate;cyclosporine
22 Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple Myeloma Completed NCT01110135 Phase 2 bendamustine hydrochloride;dexamethasone;etoposide
23 Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma Completed NCT00601718 Phase 1, Phase 2 vorinostat;ifosfamide;carboplatin;etoposide
24 Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer Completed NCT00489203 Phase 2 beclomethasone dipropionate;placebo;tacrolimus;methotrexate
25 Yttrium Y 90 Ibritumomab Tiuxetan, Fludarabine, Radiation Therapy, and Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma Completed NCT00119392 Phase 2 cyclosporine;fludarabine phosphate;mycophenolate mofetil
26 Gemcitabine Hydrochloride, Carboplatin, Dexamethasone, and Rituximab in Treating Patients With Previously Treated Lymphoid Malignancies Completed NCT00072514 Phase 2 gemcitabine hydrochloride;carboplatin;dexamethasone
27 Oblimersen Sodium and Rituximab in Treating Patients With Recurrent B-cell Non-Hodgkin Lymphoma Completed NCT00054639 Phase 2
28 Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant For Hematological Cancer Completed NCT00589563 Phase 2 cyclophosphamide;etoposide;fludarabine phosphate;melphalan;methotrexate;sirolimus;tacrolimus
29 Donor Natural Killer Cells After Donor Stem Cell Transplant in Treating Patients With Advanced Cancer Completed NCT00823524 Phase 1, Phase 2
30 Epoetin Alfa or Darbepoetin Alfa in Treating Patients With Anemia Caused by Chemotherapy Completed NCT00416624 Phase 2 darbepoetin alfa;epoetin alfa
31 Doxorubicin Hydrochloride Liposome and Bortezomib in Treating Patients With Refractory Hematologic Cancer or Malignant Solid Tumor or Metastatic Breast Cancer Completed NCT00237627 Phase 1, Phase 2 PS-341;Doxil;Velcade
32 Caspofungin Acetate in Treating Aspergillosis in Patients With Hematologic Cancer or in Patients Who Have Undergone a Stem Cell Transplant Completed NCT00110045 Phase 2 caspofungin acetate
33 Arsenic Trioxide in Treating Patients With Relapsed or Refractory Non- Hodgkin's Lymphoma Completed NCT00005040 Phase 2 arsenic trioxide
34 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Systemic Mastocytosis Completed NCT00132015 Phase 2 tanespimycin
35 Glutamine in Treating Neuropathy Caused by Vincristine in Young Patients With Lymphoma, Leukemia, or Solid Tumors Completed NCT00365768 Phase 2 Glutamine
36 Busulfan, Melphalan, and Thiotepa in Treating Patients Who Are Undergoing an Autologous Stem Cell Transplant for Hodgkin's or Non-Hodgkin's Lymphoma Completed NCT00238433 Phase 2 busulfan;melphalan;thiotepa
37 Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone With or Without Gemcitabine in Treating Patients With Previously Untreated Aggressive Non-Hodgkin's Lymphoma Completed NCT00079261 Phase 2 CHOP regimen;cyclophosphamide;doxorubicin hydrochloride;gemcitabine hydrochloride;prednisone;vincristine sulfate
38 Early Administration of ATG Followed by Cyclophosphamide, Busulfan and Fludarabine Before a Donor Stem Cell Transplant in Patients With Hematological Cancer Completed NCT00787761 Phase 2 busulfan;cyclophosphamide;fludarabine phosphate;methotrexate;tacrolimus
39 Allogeneic Hematopoietic Cell Transplantation for Patients With Busulfex-based Regimen Completed NCT00448357 Phase 1, Phase 2 busulfan;fludarabine phosphate;tacrolimus;methotrexate
40 Reduced-Intensity Busulfan and Fludarabine With or Without Antithymocyte Globulin Followed by Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease Completed NCT00448201 Phase 2 busulfan;fludarabine phosphate;methotrexate;tacrolimus
41 Treatment and Natural History Study of Lymphomatoid Granulomatosis Recruiting NCT00001379 Phase 2 Rituxan and EPOCH
42 Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies Recruiting NCT01760655 Phase 2 Fludarabine phosphate;Thiotepa;Cyclophosphamide;Tacrolimus;Mycophenolate mofetil
43 Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas Recruiting NCT03038672 Phase 2 Varlilumab
44 Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas Recruiting NCT02213913 Phase 1, Phase 2 lenalidomide;etoposide;prednisone;vincristine sulfate;doxorubicin hydrochloride;cyclophosphamide
45 A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies Recruiting NCT01384513 Phase 2 Fludarabine;Busulfan;Cyclophosphamide (CY);Tacrolimus;Mycophenolate mofetil
46 Donor Stem Cell Transplant in Treating Patients With Previously Treated Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia Recruiting NCT00612716 Phase 2 busulfan;cyclophosphamide
47 Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies Active, not recruiting NCT01529827 Phase 2 fludarabine phosphate;melphalan;tacrolimus;mycophenolate mofetil;methotrexate
48 Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant Active, not recruiting NCT00078858 Phase 1, Phase 2 fludarabine phosphate;cyclosporine;mycophenolate mofetil
49 Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer Active, not recruiting NCT00006251 Phase 1, Phase 2 fludarabine phosphate;cyclosporine;mycophenolate mofetil
50 Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies Active, not recruiting NCT01839916 Phase 2

Search NIH Clinical Center for Lymphomatoid Granulomatosis

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Lymphomatoid Granulomatosis cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Lymphomatoid Granulomatosis:
Blood stem cell transplantation for hematological diseases
Hematopoietic stem cells for treatment of hematologic malignancies
Embryonic/Adult Cultured Cells Related to Lymphomatoid Granulomatosis:
Peripheral blood-derived hematopoietic stem cells (family)
Bone marrow-derived hematopoietic stem cells
Sources

Genetic Tests for Lymphomatoid Granulomatosis

About this section
Sources

Anatomical Context for Lymphomatoid Granulomatosis

About this section

MalaCards organs/tissues related to Lymphomatoid Granulomatosis:

41
Lung, B Cells, Skin, Liver, T Cells, Kidney, Bone
Sources

Publications for Lymphomatoid Granulomatosis

About this section

Articles related to Lymphomatoid Granulomatosis:

(show top 50) (show all 439)
# Title Authors Year
1
Oral Manifestation of Lymphomatoid Granulomatosis. ( 29542064 )
2018
2
Lymphomatoid Granulomatosis in a 14-Year-Old Boy with Trisomy 21 and History of B-Lymphoblastic Leukemia/Lymphoma. ( 29336635 )
2018
3
Lymphomatoid granulomatosis and large granular lymphocyte leukemia, a rare association of two lymphoproliferative disorders. ( 29473430 )
2018
4
Primary lymphomatoid granulomatosis in the central nervous system: A report of three cases. ( 29635846 )
2018
5
Pulmonary lymphomatoid granulomatosis diagnosed by image-guided core needle biopsy. ( 29020803 )
2018
6
Lymphomatoid Granulomatosis with Isolated Cutaneous lesions : Prolonged remission after" DAEPOCH" protocol. ( 29856361 )
2018
7
The Spontaneous Regression of Grade 3 Methotrexate-related Lymphomatoid Granulomatosis: A Case Report and Literature Review. ( 29877270 )
2018
8
Cartilage hair hypoplasia with cutaneous lymphomatoid granulomatosis. ( 29744913 )
2018
9
Angiocentric lymph proliferative disorder (lymphomatoid granulomatosis) in a person with newly-diagnosed HIV infection: a case report. ( 29739366 )
2018
10
Pitfall of <sup>18</sup>F-FDG PET/CT in Characterization of Relapsed Multisystem Lymphomatoid Granulomatosis. ( 29884684 )
2018
11
Coincidence of lymphomatoid granulomatosis, chronic myelomonocytic leukemia, and anaplastic T cell lymphoma after methotrexate therapy for rheumatoid arthritis. ( 29982850 )
2018
12
Lymphomatoid granulomatosis: A case series from South India. ( 29676363 )
2018
13
Cutaneous lymphomatoid granulomatosis with long-term absence of lung involvement. ( 30010204 )
2018
14
Unique case of trigeminal neuralgia due to Epstein-Barr-virus-associated B-cell lymphomatoid granulomatosis of the Meckel's cave and cavernous sinus: Important clinical and therapeutic implications. ( 30105142 )
2018
15
Oral ulceration: an unusual manifestation of lymphomatoid granulomatosis. ( 30284019 )
2018
16
Lymphomatoid granulomatosis mimicking cancer and sarcoidosis. ( 30288554 )
2018
17
Case 259: Primary Central Nervous System Lymphomatoid Granulomatosis Mimicking Chronic Lymphocytic Inflammation with Pontine Perivascular Enhancement Responsive to Steroids (CLIPPERS). ( 30332362 )
2018
18
Lymphomatoid granulomatosis: a rare lymphoproliferative disease in the pediatric age. ( 30337062 )
2018
19
Lymphomatoid Granulomatosis: A Rare Tumor with Poor Prognosis. ( 28838746 )
2017
20
Cutaneous human immunodeficiency virus (HIV)-associated lymphomatoid granulomatosis: complete regression following antiretroviral therapy. ( 28188620 )
2017
21
The Complete Remission of Acquired Immunodeficiency Syndrome-associated Isolated Central Nervous System Lymphomatoid Granulomatosis: A Case Report and Review of the Literature. ( 28824078 )
2017
22
Rare case of pulmonary lymphomatoid granulomatosis in conjunction with tuberculosis: A case report. ( 29049243 )
2017
23
A Case of Hodgkin Lymphoma Mimicking Lymphomatoid Granulomatosis Diagnosed at Autopsy. ( 29165611 )
2017
24
A Rare Case of Pulmonary Lymphomatoid Granulomatosis. ( 28810098 )
2017
25
Lymphomatoid granulomatosis with pulmonary and gastrointestinal involvement. ( 28167690 )
2017
26
Unsuspected lymphomatoid granulomatosis in a patient with antisynthetase syndrome. ( 29136066 )
2017
27
DOCK 8 Deficiency, EBV+ Lymphomatoid Granulomatosis, and Intrafamilial Variation in Presentation. ( 28293550 )
2017
28
Lymphomatoid Granulomatosis: A Single Institution Experience and Review of the Literature. ( 27521314 )
2016
29
Lymphomatoid granulomatosis - A rare pulmonary lymphoproliferative disease. ( 26898887 )
2016
30
Lymphomatoid Granulomatosis: Two Different Phenotypes of Computed Tomography Findings. ( 27768635 )
2016
31
Lymphomatoid granulomatosis of the brain: A case report. ( 27656321 )
2016
32
Lymphomatoid granulomatosis associated with azathioprine use for immune-mediated neuropathy. ( 27671987 )
2016
33
Lymphomatoid Granulomatosis with Paraneoplastic Polymyositis: A Rare Malignancy with Rare Complication. ( 26966605 )
2016
34
Course of IL-2-inducible T-cell kinase deficiency in a family: lymphomatoid granulomatosis, lymphoma and allogeneic bone marrow transplantation in one sibling; and death in the other. ( 27454071 )
2016
35
Lymphomatoid granulomatosis initially presenting as ulcerated subcutaneous and muscle lesions without pulmonary involvement. ( 27988929 )
2016
36
Pulmonary Lymphomatoid Granulomatosis- a Case Report with Review of Literature. ( 27872542 )
2016
37
Lymphomatoid granulomatosis coronary vasculitis and cardiomyopathy: Depiction of extent and severity on cardiac CT. ( 27021253 )
2016
38
Cerebral and pulmonary lymphomatoid granulomatosis and EBV positive oesophageal ulcer in an immunosuppressed renal transplant patient staged and followed with serial MRI and 18F-FDG PET/CT after rituximab therapy. ( 30459997 )
2016
39
Primary Orbital Lymphomatoid Granulomatosis in a 1-Year-Old Child. ( 26692728 )
2015
40
Granulomatous Lymphoproliferative Disorders: Granulomatous Slack Skin and Lymphomatoid Granulomatosis. ( 26143428 )
2015
41
A case of lymphomatoid granulomatosis presenting with cutaneous lesions. ( 27051739 )
2015
42
Fever, Dry Cough and Exertional Dyspnea: Pulmonary Lymphomatoid Granulomatosis Masquerading as Pneumonia, Granulomatosis with Polyangiitis and Infectious Mononucleosis. ( 26631890 )
2015
43
Lymphomatoid granulomatosis mimicking vasculitis. ( 26382276 )
2015
44
Pathology in Practice. Lymphomatoid granulomatosis of lung tissue and mediastinal lymph node in a dog. ( 26517613 )
2015
45
Clinical, imaging and histopathological features of isolated CNS lymphomatoid granulomatosis. ( 25709167 )
2015
46
Lymphomatoid Granulomatosis. ( 26386275 )
2015
47
Pulmonary lymphomatoid granulomatosis. A rare entity in the differential diagnosis of pulmonary nodules. ( 26078192 )
2015
48
Biopsy-proven muscular involvement of lymphomatoid granulomatosis assessed by (18)FDG-PET Scan. ( 25623523 )
2015
49
Primary cerebral lymphomatoid granulomatosis progressing to methotrexate-associated lymphoproliferative disease under immunosuppressive therapy. ( 25758078 )
2015
50
Lymphomatoid Granulomatosis with Central Nervous System Involvement Successfully Treated with Cyclophosphamide, High-dose Cytarabine, Dexamethasone, Etoposide, and Rituximab (CHASER therapy) Followed by Brain Irradiation: A Case Study. ( 26096049 )
2015
Sources

Variations for Lymphomatoid Granulomatosis

About this section
Sources

Expression for Lymphomatoid Granulomatosis

About this section
Search GEO for disease gene expression data for Lymphomatoid Granulomatosis.
Sources

Pathways for Lymphomatoid Granulomatosis

About this section

Pathways related to Lymphomatoid Granulomatosis according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Toll-like Receptor Signaling Pathway 37 1
Show member pathways
 12.35 CXCL9 IFNA1 IFNA2
2
Necroptosis 37
Show member pathways
 11.69 IFNA1 IFNA2
3
Allograft rejection 1 37
Show member pathways
 11.66 CXCL9 GZMB IFNA1 IFNA2
4
Factors involved in megakaryocyte development and platelet production 66
11.63 IFNA1 IFNA2
5
Immune response Role of DAP12 receptors in NK cells 22
Show member pathways
 11.61 GZMB IFNA1 IFNA2
6
Hepatitis C 37
11.52 IFNA1 IFNA2
7
Jak-Stat Signaling Pathway (sino) 67
11.31 IFNA1 IFNA2
8
all-trans-Retinoic Acid Mediated Apoptosis 64
10.89 IFNA1 IFNA2
9
Type II interferon signaling (IFNG) 1
10.72 CXCL9 IFNA2
Sources

GO Terms for Lymphomatoid Granulomatosis

About this section

Biological processes related to Lymphomatoid Granulomatosis according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 apoptotic process GO:0006915 9.69 GZMB IFNA2 TIA1
2 regulation of signaling receptor activity GO:0010469 9.63 CXCL9 IFNA1 IFNA2
3 B cell differentiation GO:0030183 9.49 IFNA1 IFNA2
4 type I interferon signaling pathway GO:0060337 9.48 IFNA1 IFNA2
5 humoral immune response GO:0006959 9.43 IFNA1 IFNA2
6 B cell proliferation GO:0042100 9.4 IFNA1 IFNA2
7 response to exogenous dsRNA GO:0043330 9.37 IFNA1 IFNA2
8 T cell activation involved in immune response GO:0002286 9.32 IFNA1 IFNA2
9 positive regulation of peptidyl-serine phosphorylation of STAT protein GO:0033141 9.26 IFNA1 IFNA2
10 natural killer cell activation involved in immune response GO:0002323 9.16 IFNA1 IFNA2
11 defense response to virus GO:0051607 9.13 CXCL9 IFNA1 IFNA2
12 defense response GO:0006952 8.8 CXCL9 IFNA1 IFNA2

Molecular functions related to Lymphomatoid Granulomatosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine receptor binding GO:0005126 9.16 IFNA1 IFNA2
2 cytokine activity GO:0005125 9.13 CXCL9 IFNA1 IFNA2
3 type I interferon receptor binding GO:0005132 8.62 IFNA1 IFNA2
Sources

Sources for Lymphomatoid Granulomatosis

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....